Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling.

导出 OA

翻译打印收藏纠错

作者： Hannah L,Smith ^[1] ; Elaine,Willmore ^[1] ; Asima,Mukhopadhyay ^[2] ; Yvette,Drew ^[3] ; Nicola J,Curtin ^[1]

作者单位： Faculty of Medical Sciences, Newcastle University Centre for Cancer, Newcastle upon Tyne NE1 7RU, UK. ^[1] Kolkata Gynecological Oncology Trials and Translational Research Group, Chittaranjan National Cancer Institute, 37 SP Mukherjee Road, Kolkata 700026, India. ^[2] BC Cancer Centre Vancouver and Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada. ^[3]

关键词 ATR DDR PARP1 durability

DOI 10.3390/cancers14225559

PMID 36428653

发布时间 2022-12-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cancers

2022年14卷22期

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling.

Cancers

相似文献

Cancers

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling.

Cancers

相似文献

Cancers

相关期刊

检索历史清除